Is macituximab/magenex an ADC drug?

Margetuximab is not an antibody drug conjugate (ADC), but an Fc-engineered monoclonal antibody whose core mechanism of action relies on the activation of the immune system. It targets HER2-positive tumor cells, blocks HER2 signals through antibody-specific binding, and optimizes the Fc fragment structure to enhance binding affinity to immune effector cells, thereby improving antibody-dependent cell-mediated cytotoxicity (ADCC). This design concept allows margituximab to enhance the body's own immune system's ability to clear tumor cells clinically, rather than relying on exogenous cytotoxic drugs.

Compared with ADC drugs, there are obvious differences between them. ADC consists of three parts: a targeting antibody, a chemical linker and a highly efficient cytotoxic small molecule drug. Its main mechanism is that after the antibody guides the ADC to the tumor cells, the linker releases toxins within the cell and directly damages the DNA or microtubule system of the cancer cells, thereby achieving precise killing. The advantage of ADC is that it can specifically deliver potent toxins to tumor cells, thereby reducing damage to normal tissues, but it may also cause more significant systemic toxic side effects. In contrast, the advantage of margetuximab is that it relies on the immune system to exert its anti-tumor effect. Side effects are usually related to monoclonal antibodies, such as infusion reactions or immune-related adverse events, which are relatively more controllable.

In clinical application, margetuximab is usually used for breast cancer patients whose disease has progressed after previously receiving trastuzumab or other anti-HER2 treatments. It is often used in combination with chemotherapy to improve the efficacy. Its positioning is closer to "immune-optimized monoclonal antibodies", which emphasizes improving the ability of immune cells to recognize and kill tumors through Fc engineering. ADC drugs are more commonly used in patients who want to directly kill tumor cells through drugs, especially those tumor types that are resistant to monoclonal antibodies or immunotherapy.

Reference materials:https://www.margenza.com/